Mechanisms of Gastrointestinal COVID-19
胃肠道 COVID-19 的机制
基本信息
- 批准号:10538795
- 负责人:
- 金额:$ 30.4万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-10 至 2022-07-14
- 项目状态:已结题
- 来源:
- 关键词:16S ribosomal RNA sequencing2019-nCoVACE2Abdominal PainAcuteAddressAdrenal Cortex HormonesAffectAutomobile DrivingCOVID-19COVID-19 patientCOVID-19 severityCOVID-19 vaccinationCathepsin LCathepsinsCathepsins BCell DeathCellsChronicClinicalColitisConfusionCoronavirusCrohn&aposs diseaseDataDiarrheaDiseaseEnteralEnterocytesEnvironmental Risk FactorEpithelialEpithelial CellsEtiologyFecesFoundationsFunctional disorderFutureGastrointestinal DiseasesGastrointestinal PhysiologyGastrointestinal tract structureGenotypeHealthHomeostasisHouseholdHumanImmuneImmune responseImpairmentInfectionInflammationInflammatory Bowel DiseasesIntegration Host FactorsInternationalIntestinal ContentIntestinal DiseasesIntestinesInvestigationK-18 conjugateKnowledgeLate EffectsLeadLiquid substanceLiteratureLower Gastrointestinal TractMesalamineModelingMolecularMucosal Immune ResponsesMucosal ImmunityMucositisMusNausea and VomitingObservational StudyOrganoidsOutcomePathogenesisPathogenicityPathologyPathway interactionsPatientsPharmaceutical PreparationsPhenotypePopulations at RiskRecommendationReporterReportingRespiratory SystemSARS-CoV-2 P.1SARS-CoV-2 infectionSamplingSeverity of illnessSignal TransductionSmall IntestinesSouth AfricanSpecimenStandardizationSymptomsTNF geneTestingTherapeuticTherapeutic immunosuppressionTransgenic MiceTropismViral Load resultViral reservoirVirusVirus ReplicationVulnerable Populationsacute infectionbasebile saltsbiobankclinical careclinical practicedifferential expressiondisease diagnosisenteric infectionexperiencegastrointestinalgastrointestinal symptomgut dysbiosisgut inflammationgut microbiomehost-microbe interactionsinfection rateinhibitorintestinal epitheliummicrobiomemicrobiome therapeuticsmicrobiotamortalitynovelnovel coronavirusrespiratorysocioeconomicsstool samplesurveillance studytoolvirologyviromevirus resource
项目摘要
Project Summary
Although coronavirus disease 2019 (COVID-19) is primarily defined as a respiratory illness, patients often
experience clinical gastrointestinal symptoms, including abdominal pain and diarrhea. We recently found that
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, infects and
replicates in human small bowel intestinal epithelial cells (IECs). However, the molecular mechanisms of SARS-
CoV-2 driving gastrointestinal pathology, particularly in vulnerable populations with preexisting diseases remain
unclear.
In this proposal, our overall objectives are to better define the cellular signaling of SARS-CoV-2 interactions
with IECs, enteric immune responses, and microbiome in the context of health or inflammatory bowel disease
(IBD). Our preliminary data suggest that compared to normal COVID-19 patients, those with IBD have higher
expression of cathepsin L in IECs, which correlated with higher viral loads. Our central hypothesis is that SARS-
CoV-2 induces a distinctive intestinal pathology and mucosal immune response that is shaped by host factors
(IBD), luminal factors (secretions, bile salts, and microbiome), and therapeutics (mesalamine). Specifically, using
healthy and IBD-derived organoids, COVID-19 patient fecal samples, and K18-hACE2 mice, we aim to (1) define
the host factors and cellular mechanisms involved in SARS-CoV-2 infection of normal and IBD epithelium, (2)
determine the impact of intestinal SARS-CoV-2 infection on intestinal immune response and colitis, and (3)
define the environmental factors that influence intestinal infection with SARS-CoV-2.
With extensive and collaborative expertise in IBD, virology, and host-microbial interactions, we expect to
address mechanistically interesting and clinically important questions like “What is the intestinal pathogenicity of
SARS-CoV-2 and how is it impacted by IBD?”, “What is the interaction of SARS-CoV-2/COVID-19 with intestinal
inflammation and IBD therapies?”, and “What is the impact of intestinal contents and IBD diagnosis/microbiome
on intestinal SARS-CoV-2?”. We anticipate that this pathology will further our understanding of SARS-CoV-2
interactions with the epithelial and immune cells to explain COVID-19 GI symptoms with or without IBD. We also
expect the new information gained from this project will expand our understanding of acute gastrointestinal
pathology and symptoms of COVID-19, provide mechanistic context to existing clinical and translational literature,
and create a foundational knowledge and tool set for deeper investigations into COVID-19 and potentially
pathogenic and emerging coronaviruses of the future.
项目摘要
虽然冠状病毒病2019(新冠肺炎)最初被定义为一种呼吸系统疾病,但患者往往
出现临床胃肠道症状,包括腹痛和腹泻。我们最近发现,
引起新冠肺炎的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染和
在人小肠上皮细胞(IECS)中复制。然而,SARS的分子机制--
驱动胃肠道病理的CoV-2病毒,特别是在有既往疾病的易感人群中仍然存在
不清楚。
在这项提案中,我们的总体目标是更好地定义SARS-CoV-2相互作用的细胞信号
在健康或炎症性肠病的背景下,IECS、肠道免疫反应和微生物组
(IBD)。我们的初步数据表明,与正常的新冠肺炎患者相比,IBD患者的
组织蛋白酶L在血管内皮细胞中的表达与病毒载量增加有关。我们的中心假设是SARS-
CoV-2诱导一种由宿主因素塑造的独特的肠道病理和粘膜免疫反应
肠易激综合征(IBD)、腔因子(分泌物、胆盐和微生物组)和治疗药物(美沙拉明)。具体地说,使用
健康和炎症性肠病衍生的有机类化合物,新冠肺炎患者的粪便样本,以及K18-hACE2小鼠,我们的目标是(1)定义
SARS-CoV-2感染正常和IBD上皮的宿主因素和细胞机制,(2)
确定肠道感染SARS-CoV-2对肠道免疫反应和结肠炎的影响,以及(3)
明确影响SARS-CoV-2肠道感染的环境因素。
凭借在IBD、病毒学和宿主-微生物相互作用方面的广泛和协作专业知识,我们希望
解决机械上有趣的和临床上重要的问题,如“什么是肠道致病性
SARS-CoV-2及其受传染性法氏囊病的影响?“,”SARS-CoV-2/新冠肺炎与肠道的相互作用
炎症和IBD治疗?“,以及”肠道内容物和IBD诊断/微生物组有什么影响?“
肠道SARS-CoV-2?“。我们预计,这一病理将加深我们对SARS-CoV-2的了解
与上皮细胞和免疫细胞的相互作用解释伴有或不伴有IBD的新冠肺炎胃肠道症状。我们也
希望从这个项目中获得的新信息将扩大我们对急性胃肠道疾病的理解
新冠肺炎的病理和症状,为现有的临床和翻译文献提供了机械性的背景,
并为更深入地调查新冠肺炎和潜在的
未来的致病性和新兴冠状病毒。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Re-Examining Rotavirus Innate Immune Evasion: Potential Applications of the Reverse Genetics System.
- DOI:10.1128/mbio.01308-22
- 发表时间:2022-08-30
- 期刊:
- 影响因子:6.4
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MATTHEW AARON CIORBA其他文献
MATTHEW AARON CIORBA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MATTHEW AARON CIORBA', 18)}}的其他基金
Targeting Tryptophan Metabolism in Rectal Cancer
靶向直肠癌中的色氨酸代谢
- 批准号:
10754178 - 财政年份:2023
- 资助金额:
$ 30.4万 - 项目类别:
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER
针对结肠炎相关癌症中的色氨酸代谢
- 批准号:
9270026 - 财政年份:2016
- 资助金额:
$ 30.4万 - 项目类别:
TARGETING TRYPTOPHAN METABOLISM IN COLITIS ASSOCIATED CANCER
针对结肠炎相关癌症中的色氨酸代谢
- 批准号:
9083887 - 财政年份:2016
- 资助金额:
$ 30.4万 - 项目类别:
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer
结肠炎相关癌症中的吲哚胺 2,3 双加氧酶
- 批准号:
7962872 - 财政年份:2010
- 资助金额:
$ 30.4万 - 项目类别:
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer
结肠炎相关癌症中的吲哚胺 2,3 双加氧酶
- 批准号:
8079485 - 财政年份:2010
- 资助金额:
$ 30.4万 - 项目类别:
Indoleamine 2,3 Dioxygenase in Colitis Associated Cancer
结肠炎相关癌症中的吲哚胺 2,3 双加氧酶
- 批准号:
8500253 - 财政年份:2010
- 资助金额:
$ 30.4万 - 项目类别:
相似国自然基金
微米和纳米塑料作用下2019-nCoV抗病毒药物利巴韦林对河蚬的毒性作用机制
- 批准号:
- 批准年份:2021
- 资助金额:10.0 万元
- 项目类别:省市级项目
2019-nCoV感染导致人体淋巴细胞减低机制及其对机体免疫功能影响
- 批准号:82030002
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:专项基金项目
基于人口流动大数据的新型冠状病毒(2019-nCoV)输出感染风险及接触网络传播模型研究
- 批准号:
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:
新型冠状病毒(2019-nCoV)反向遗传系统及啮齿类感染模型的建立与应用
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:
血必净预防2019-nCoV肺炎发生ARDS及机制研究
- 批准号:82041003
- 批准年份:2020
- 资助金额:135 万元
- 项目类别:专项基金项目
云南驯养野生动物中新型冠状病毒(2019-nCoV)溯源调查与验证
- 批准号:
- 批准年份:2020
- 资助金额:140 万元
- 项目类别:
新型冠状病毒2019-nCoV复制复合体关键蛋白的功能与潜在药物靶点研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
2019-nCoV蝙蝠及人群代表性流行株致病能力的比较研究
- 批准号:
- 批准年份:2020
- 资助金额:150 万元
- 项目类别:专项基金项目
人新型冠状病毒2019-nCoV受体利用介导的种间传播和感染机制研究
- 批准号:
- 批准年份:2020
- 资助金额:140 万元
- 项目类别:专项基金项目
新型冠状病毒(2019-nCoV)恢复期感染者针对病毒表面spike蛋白的多克隆抗体反应研究
- 批准号:32000661
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
COVID-19 Variant Supplement - Targeting programmed ribosomal frameshifting as a therapeutic strategy against 2019-nCoV
COVID-19 变异补充剂 - 以程序化核糖体移码为目标作为针对 2019-nCoV 的治疗策略
- 批准号:
443173 - 财政年份:2021
- 资助金额:
$ 30.4万 - 项目类别:
Operating Grants
Destigmatizing Chinese Communities in the face of 2019-nCoV: Emergency Management Actions to Address Social Vulnerability in Toronto and Nairobi
面对 2019-nCoV,消除华人社区的污名化:解决多伦多和内罗毕社会脆弱性的应急管理行动
- 批准号:
422610 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Operating Grants
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10330359 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10454575 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10454574 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10579807 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Targeting programmed ribosomal frameshifting as a therapeutic strategy against 2019-nCoV
以程序化核糖体移码为目标作为针对 2019-nCoV 的治疗策略
- 批准号:
422724 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Operating Grants
Task A38: Establishment of Small Animal Models for Screening Medical Countermeasures for the 2019 Novel Coronavirus (2019-nCoV)
任务A38:建立用于筛选2019新型冠状病毒(2019-nCoV)医疗对策的小动物模型
- 批准号:
10464972 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Task A38: Establishment of Small Animal Models for Screening MCMs for the 2019 Novel Coronavirus (2019-nCoV)
任务 A38:建立用于筛选 2019 年新型冠状病毒(2019-nCoV)的 MCM 的小动物模型
- 批准号:
10473626 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
RAPID Proposal: Psychological distance and risk perception related to the 2019 novel coronavirus (2019-nCoV) outbreak
RAPID提案:与2019年新型冠状病毒(2019-nCoV)爆发相关的心理距离和风险感知
- 批准号:
2020597 - 财政年份:2020
- 资助金额:
$ 30.4万 - 项目类别:
Standard Grant














{{item.name}}会员




